by Clinical Neuropsychologist Online | Friday, November 8, 2024 | Dementia
Abstract INTRODUCTION Despite the recognized importance of including ethnic diversity in Alzheimer’s disease (AD) research, substantial knowledge gaps remain, particularly in Asian populations. METHODS RNA sequencing was performed on blood samples from the...
by Clinical Neuropsychologist Online | Friday, November 8, 2024 | Dementia
Abstract INTRODUCTION Semorinemab, an anti-tau monoclonal antibody, was assessed in two Phase II trials for Alzheimer’s disease (AD). Plasma and cerebrospinal fluid (CSF) biomarkers provided insights into the drug’s potential mechanism of action. METHODS...
by Clinical Neuropsychologist Online | Friday, November 8, 2024 | Dementia
Abstract Dementia prevention in Africa is critically underexplored, despite the continent’s high prevalence of modifiable risk factors. With a predominantly young and middle-aged population, Africa presents a prime opportunity to implement evidence-based...
by Clinical Neuropsychologist Online | Friday, November 8, 2024 | Dementia
Abstract INTRODUCTION The Health Equity Scholars Program (HESP) addresses the critical need for a diverse, culturally competent workforce to study and treat older adults from underrepresented populations (URPs) with Alzheimer’s disease and related dementias...
by Clinical Neuropsychologist Online | Friday, November 8, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) is the most common form of dementia in the elderly. Given that AD neuropathology begins decades before symptoms, there is a dire need for effective screening tools for early detection of AD to facilitate early...
